Table 2.
Multivariate Cox proportional hazards regression analyses for overall and cancer-specific mortality in patients with leiomyosarcoma or carcinosarcoma
| Leiomyosarcoma | Carcinosarcoma | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall a | Cancer-specific b | Overall c | Cancer-specific d | |||||
| Variables | aHR (95% CI) | P-value | aHR (95% CI) | P-value | aHR (95% CI) | P-value | aHR (95% CI) | P-value |
| Adjuvant radiotherapy | ||||||||
| No treatment | reference | reference | reference | reference | ||||
| EBRT alone | 0.90 (0.54, 1.51) | 0.697 | 0.91 (0.51, 1.64) | 0.760 | 0.72 (0.53, 0.99) | 0.042 | 0.78 (0.54, 1.14) | 0.199 |
| Brachytherapy alone | 0.57 (0.14, 2.31) | 0.429 | 0.47 (0.07, 3.38) | 0.452 | 0.55 (0.37, 0.80) | 0.002 | 0.51 (0.31, 0.84) | 0.009 |
| Combination radiotherapy e | NA | NA | NA | NA | 0.47 (0.29, 0.77) | 0.003 | 0.53 (0.29, 0.95) | 0.034 |
| Age | ||||||||
| < 60 years | reference | reference | ||||||
| ≥ 60 years | 1.55 (1.11, 2.18) | 0.011 | 1.74 (1.27, 2.37) | 0.001 | ||||
| AJCC Stage | ||||||||
| Stage I | reference | reference | reference | reference | ||||
| Stage II | 1.82 (1.15, 2.89) | 0.011 | 1.85 (1.09, 3.12) | 0.022 | 1.06 (0.67, 1.69) | 0.802 | 1.10 (0.61, 1.98) | 0.758 |
| Stage III | 3.07 (2.01, 4.69) | < 0.001 | 3.21 (2.02, 5.13) | < 0.001 | 2.36 (1.88, 2.97) | < 0.001 | 2.57 (1.93, 3.42) | < 0.001 |
| Grade | ||||||||
| Grade 1 | reference | |||||||
| Grade 2 | 1.58 (0.18, 13.60) | 0.679 | ||||||
| Grade 3 | 7.17 (0.97, 52.86) | 0.053 | ||||||
| Undifferentiated/anaplastic | 5.08 (0.69, 37.09) | 0.110 | ||||||
| Tumor size | ||||||||
| ≤ 50 mm | reference | reference | reference | |||||
| > 50 mm | 2.98 (1.38, 6.45) | 0.006 | 1.96 (1.50, 2.57) | < 0.001 | 2.07 (1.46, 2.93) | < 0.001 | ||
| Lymphadenectomy | ||||||||
| No | reference | reference | ||||||
| Yes | 0.61 (0.47, 0.78) | < 0.001 | 0.61 (0.45, 0.84) | 0.003 | ||||
aHR adjusted hazard ratio, CI confidence interval, EBRT external beam radiation therapy, AJCC American Joint Committee on Cancer
aModel was adjusted by age group, and stage, grade
bModel was adjusted by stage, and tumor size
cModel was adjusted by age group, stage, tumor size, and lymphadenectomy
dModel was adjusted stage, tumor size, and lymphadenectomy
eCombination radiotherapy: combination of EBRT and either radioactive implants or radioisotopes
NA, not available because no patient died during the study period
Unknown data for adjuvant radiotherapy, AJCC stage, grade, tumor size, and lymphadenectomy status were not shown in the table
Bold text indicates a significant difference with a p-value less than 0.05 compared to the reference group